An optimized, sensitive and validated reversed-phase high-performance liquid chromatography (RP-HPLC) method with UV detection is described for simultaneous determination of esculin and its aglycone, esculetin, in rat plasma. After addition of internal standard (chrysin), plasma samples were pretreated by solid-phase extraction and introduced into the HPLC system. Analytes were separated on a RP C18 column with a mobile phase of 0.075% acetic acid in water (solvent A) and 90% acetonitrile in solvent A (solvent B) using gradient elution at a flow rate of 1.0 mL/min. The wavelength for UV detection was set at 338 nm. Calibration curves for esculin and esculetin were constructed over a range of 10 -1,000 ng/mL. The developed method was found to be specific, precise and accurate. The method was successfully applied to study the pharmacokinetics of esculin and esculetin in rats. After oral administration of 120 mg/kg, the mean C max values were 340.3 and 316.5 ng/mL and the AUC last values were 377.3 and 1276.5 h ng/mL for esculin and esculetin, respectively. The bioavailability of esculin was calculated to be 0.62%.
Introduction
Esculin, a coumarin glucoside, is one of the major bioactive constituents in Cortex fraxini, a commonly used herbal medicine in Asian countries (1) . Cortex fraxini is the dried bark of plants from the Oleaceae family, including Fraxinus rhynchophylla, F. chinensis, F. szaboana and F. stylosa (2, 3) . Cortex fraxini exhibits multiple biological actions, including intestinal antiinflammatory activity, anti-oxidant activity and anti-cancer activity (4 -7) .
Esculetin is an aglycone metabolite of esculin and is one of the simplest coumarins, with two hydroxyl groups at carbons 6 and 7. It is also a principal bioactive constituent of Cortex fraxini. Esculetin has strong anti-oxidant and photo-protective activities (8) . Esculetin also has multiple immunomodulatory effects on murine lymphocytes and peritoneal macrophages in the rat liver (9) . In addition, it shows anti-inflammatory activity, inhibition of lipoxygenase and tyrosinase activity, scavenging of hydroxyl radicals and suppression of lipid peroxidation (10) .
Although the biological and pharmacological activities of esculin and esculetin have been extensively investigated, there are only limited data with respect to their pharmacokinetic properties (10 -13) . These studies have reported pharmacokinetic parameters for esculin or esculetin after esculin administration via a single route, such as intraperitoneal (i.p.), oral or topical, in rats or rabbits. There are no data available on the oral bioavailability of esculin.
Bioanalytical methods for esculin have been developed and reported along with pharmacokinetic studies of esculetin.
High-performance liquid chromatography (HPLC) with ultraviolet (UV) or fluorescence detection has been developed for determination of esculin in biological fluids (11, 12) . Recently, HPLC coupled with tandem mass spectrometry (LC -MS-MS) or quadrupole time-of-flight mass spectrometer (QTOF/MS) has been reported (10, 13). However, it was our goal to develop a simple and general bioanalytical method, which can be used for pharmacokinetic studies of esculin. Accordingly, we designed a simple, sensitive and reliable reversed-phase HPLC (RP-HPLC) method for the simultaneous determination of esculin and esculetin in rat plasma. In this study, we report the development and validation of this method and, using this method, have performed pharmacokinetic studies to determine the oral bioavailability of esculin in rats.
Experimental
Chemicals and reagents Esculin (.98%), esculetin (.98%) and chrysin (.97%) ( Figure 1 ) were purchased from Sigma-Aldrich (St Louis, MO, USA). HPLC-grade acetonitrile and methanol were purchased from J.T. Baker (Phillipsburg, NJ, USA). HPLC-grade water was prepared using a Milli-Q purification system (Millipore, Bedford, MA, USA). All chemical and solvents were of analytical or HPLC grade. All standard solutions and mobile phases were passed through a 0.22 mm membrane filter before use.
Preparation of calibration standards and quality control samples Stock solutions were prepared in methanol to yield final concentrations of 100 mg/mL esculin, 100 mg/mL esculetin and 50 mg/mL chrysin, the internal standard (IS). The stock solutions were stored at 48C and brought to room temperature before use. Standard solutions were prepared by diluting the stock solutions with 70% methanol to final concentrations ranging from 0.5 to 10 mg/mL. The IS solution was prepared by diluting the IS stock solution with 70% methanol to yield a concentration of 5 mg/mL.
The standard solutions (100 mL) were added to rat plasma (900 mL) to yield the calibration standards of 10, 20, 50, 100, 200, 500 and 1,000 ng/mL. Quality control (QC) samples were prepared at final concentrations of 10, 100 and 1,000 ng/mL in the same way as the calibration standards. The calibration standards and QC samples were kept frozen at 2208C until use.
Sample preparation A 10-mL aliquot of IS solution was added to the calibration standard, QC sample or plasma sample (90 mL) and vortexed for 3 min. Solid-phase extraction (SPE) Oasis cartridges (HLB 96-well plate, 30 mm; Waters Co., Milford, MA, USA) were activated with 1 mL of methanol followed by 1 mL of 0.1% acetic acid in water. Plasma samples with IS were introduced into the cartridge under vacuum and then washed two times with 1 mL of 0.1% acetic acid. The analytes were eluted with 1 mL of methanol. The eluent was evaporated to dryness by a gentle stream of nitrogen at 408C. The residues were reconstituted in 100 mL of 30% methanol in water, and a 50-mL aliquot was injected into the HPLC system. , the mobile phase was pumped through the system at a flow rate of 1.0 mL/min. Fifty microliters of sample solution was injected onto the column. The wavelength of the UV detector was set at 338 nm.
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Method validation
The specificity of the assay was evaluated by comparing chromatograms of the blank and standard-spiked plasma samples. Recovery was calculated by comparing the respective peak areas of the chromatograms of the extracted samples with the untreated standard solutions containing a known amount of the compounds. Calibration curves were constructed and fit by linear least-squares regression analysis to plot the peak area ratio of analytes to IS vs. the analyte concentrations. The lower limit of quantification (LLOQ) was defined as the lowest concentration with a relative standard deviation (RSD) of ,20% and accuracy of 80 -120%. The accuracy and precision of the method were evaluated by repeated analyses of QC samples (n ¼ 3) at concentrations of 10, 100 and 1,000 ng/mL on three consecutive days.
The stability of esculin and esculetin in stock solutions was evaluated at 48C for 2 months and at room temperature for 24 h, in triplicate at three concentrations (i.e. 10, 100 and 1,000 ng/mL). Esculin and esculetin short-term and long-term stability in rat plasma was also evaluated in triplicate at three concentrations (10, 100 and 1,000 ng/mL). For short-term stability studies, the QC samples were stored at room temperature for 12 h and were then analyzed. For long-term stability studies, the QC samples were stored at 2208C for 28 days and then analyzed. For freeze-thaw stability, the QC samples were stored at 2208C for 24 h and thawed at room temperature. The freezethaw cycle was repeated two more times and then the samples were analyzed. For post-preparative stability studies, the QC samples were analyzed after storing at 48C for 24 h. The analytes were considered stable under storage conditions if the percent recovery was found to be 90 -110% of the nominal initial concentration.
Application to a pharmacokinetic study in rats Sprague-Dawley male rats (age, 8 weeks; weight, 230 -250 g) were purchased from Orient Bio. (Songnam, Korea) and housed in a temperature (23 + 38C) and moisture-controlled (55 + 15% relative humidity) room and with a controlled 12 h light -dark cycle and access to food and water ad libitum. The rats were fasted for 12 h and had free access to water before dosing. On the day before the pharmacokinetic study, a polyethylene tube was surgically implanted into the carotid artery for obtaining blood samples. An additional polyethylene tube was implanted into the jugular vein for injections of intravenous doses. Rats were divided into three groups of six rats each: esculin orally administered (120 mg/kg), esculetin orally administered (120 mg/kg) and esculin intravenously (i.v.) administered (5 mg/kg). Oral dosing solutions were prepared in 0.50% sodium carboxy methyl cellulose (CMC -Na) suspension and i.v. dosing solutions were prepared in isotonic saline. Serial blood samples (200 mL) were collected from the carotid into heparinized 1.5 mL polythene tubes before dosing and at 5, 10, 15, 20, 30 and 45 min, and at 1, 1.5, 2, 3, 4, 6, 8 12, and 24 h after dosing, centrifuged at 13,200 rpm for 5 min and stored frozen at 2208C until analysis. Rat plasma samples (90 mL) were spiked with IS and processed as described above. All animal procedures were approved by the Institutional Animal Care and Use Committee of Hanyang University (2013-184).
Pharmacokinetic analysis
Pharmacokinetic parameters from rat plasma samples were calculated by a non-compartmental statistical model using Phoenix WinNonlin Enterprise Program v5.3 (Pharsight Inc., St Louis, MO, USA). The maximum plasma concentration (C max ) and the time to reach C max (T max ) were directly obtained from the experimental data. The elimination half-life (t 1/2 ) was calculated as 0.693/l z , where l z is the elimination rate constant calculated from the terminal linear portion of the log plasma concentration -time curve. The area under the plasma concentration-time curve (AUC) from time zero to the last quantifiable time point (AUC 0!t ) and from time zero to infinity (AUC 0!1 ) were estimated using the log-linear trapezoidal rule. Volume of distribution based on the terminal phase (V z ) and total body clearance (Cl) are directly obtained from the experimental data processed by the WinNonlin software. By using the p.o. and i.v. Representative chromatograms of (A) blank rat plasma, (B) plasma spiked with esculin, esculetin (50 ng/mL, each) and chrysin (IS, 500 ng/mL) and (C) plasma sample obtained 15 min after oral administration esculin (120 mg/kg). 1, Esculin; 2, esculetin and 3, chrysin.
pharmacokinetic data, the bioavailability (f ) of esculin was calculated.
Results
Analytical method validation
Specificity
Representative chromatograms for blank rat plasma and blank rat plasma spiked with esculin (50 ng/mL), esculetin (50 ng/mL) and IS (500 ng/mL) are shown in Figure 2A and B. Figure 2C shows the chromatogram of the rat plasma sample obtained at 15 min after oral administration of esculin. Esculin, esculetin and IS were well resolved at retention times of 10.3, 15.2 and 20.1 min, respectively. No endogenous interference was found at the retention times of esculin, esculetin and IS, indicating that the developed method is specific for all analytes.
Linearity and LLOQ
The calibration curves were obtained by plotting the peak area ratio of the analytes to IS against the corresponding concentration of the analytes in the freshly prepared plasma standards. The plasma calibration curves for esculin and esculetin were constructed using seven calibration standards (i.e., 10, 20, 50, 100, 200, 500 and 1,000 ng/mL). The calibration standard curve had a reliable reproducibility over the standard concentrations across the calibration range. The calibration curve was prepared by determining the best fit of the peak area ratios ( peak area analyte/peak area IS) vs. concentration and fitted to the equation Y ¼ aX þ b. The average regression coefficients (n ¼ 3) for esculin and esculetin were !0.999. The LLOQ in rat plasma for both esculin and esculetin was determined to be 10 ng/mL based on accuracies of 95.7 and 96.3% and precisions of 1.5 and 2.1% at this concentration for esculin and esculetin, respectively.
Accuracy and precision
Intra-and inter-day accuracy (as % recovery) and precision (as RSD) for esculin and esculetin in rat plasma were assayed with the QC samples at concentrations of 10, 100 and 1,000 ng/mL. The resulting data are presented in Table I . The intra-day precision was within 1.9 and 2.8% and the inter-day precision was within 3.2 and 5.5% for esculin and esculetin, respectively.
Recovery
To determine the recovery of esculin and esculetin in rat plasma, an aliquot of blank rat plasma was spiked with esculin and esculetin to achieve final concentrations of 10, 100 and 1,000 ng/mL (n ¼ 3). The plasma samples were then pretreated using the SPE method. Absolute recoveries of esculin and esculetin were determined by comparing peak areas of the extracted QC samples with those of the corresponding concentrations of standard solutions. The mean recoveries from rat plasma at concentrations of 10, 100 and 1,000 ng/mL were 94.3, 95.6 and 96.7% for esculin and 96.1, 97.1 and 97.2% for esculetin, respectively. The recovery of IS was 91.4% at the concentration used in this study (500 ng/mL).
Stability
The stability of esculin and esculetin in standard stock solution and in plasma was investigated. The stability results are summarized in Table II . Stock solutions of esculin and esculetin in methanol were found to be stable for at least 2 months when stored at 48C and for 24 h when stored at room temperature. Esculin and esculetin in rat plasma were stable at room temperature for 12 h. The plasma QC samples were stable when stored frozen at 2208C for at least 28 days and also stable following three cycles of freeze and thaw. These results indicated that esculin and esculetin are stable in stock solution as well as in plasma.
Pharmacokinetic application
The mean plasma concentration -time profiles for esculin and esculetin following oral administration of esculin and esculetin and following i.v. administration of esculin are shown in Figures 3 and 4 . With the LLOQ of 10 ng/mL, plasma concentrations of esculin were successfully quantified for up to 6 h after both oral and i.v. administration of esculin to rats. Plasma esculetin levels could be quantified for up to 12 h in plasma from rats given esculetin orally. The concentrations in samples taken at 8 h for esculin and at 24 h for esculetin were below the LLOQ. The basic pharmacokinetic parameters of esculin and esculetin in the rats were calculated based on the plasma concentration data. These are summarized in Table III .
Discussion
The determination of esculin in rat plasma by HPLC has already been developed by Chen et al. (11) . However, our method allows a simultaneous determination of esculin and esculetin (a metabolite of esculin) in rat plasma by using gradient elution for better resolution and peak shape. Furthermore, we have improved the HPLC method in terms of LLOQ. The LLOQ of the previous HPLC method (11) was 57.4 ng/mL whereas that of the present method is 10 ng/mL. In addition, some bioanalytical methods using different analytical instruments such as HPLC -fluorescence detector or LC-tandem mass spectrometry have been previously reported (10, 12, 13) . These methods showed LLOQ values than our method as they adopted more sensitive detectors. However, HPLC/UV systems are still more general and popular and those methods were designed only for the analysis of esculin. Esculin is the glycoside of esculetin and may be easily hydrolyzed by microbial glycosidases in the gut to yield esculetin (14) . In our pharmacokinetic study, esculetin was found only in trace amounts at several time points after oral administration of esculin (esculetin was observed in Figure 2C ). According to the report by Ding et al. (15) , esculetin is known to be metabolized to form glucuronide or sulfate conjugates after being absorbed from the gastrointestinal tract, which could explain the reason for the low plasma levels of esculetin after oral administration of esculin.
In the pharmacokinetic results using the developed method, orally administered esculin disappears from the plasma according to a one compartment open model. The parameters (Table III) indicate that esculin clears from plasma quickly, while esculetin is cleared more slowly. According to the previous report by Chen et al. (11) , after i.p. administration of esculin, it also disappears from the plasma rapidly, which is consistent with our findings. In this study, we have tested an i.v. dose of 5 mg/kg of esculin in rats and calculated the oral bioavailability of esculin, which is 0.62%. This low value reveals that esculin may have poor oral absorption and/or have a very active first pass effect.
Conclusion
In this study, we have described an optimized and valid bioanalytical RP-HPLC method for the simultaneous determination of esculin and esculetin in rat plasma. The method is sensitive, selective, accurate and reproducible. This method was successfully applied to determine esculin and esculetin in rat plasma for pharmacokinetic studies. In this article, oral bioavailability of esculin was reported for the first time. The developed method can facilitate pharmacokinetic studies for herbal medicines or food supplements containing esculin or esculetin as a principal ingredient. 
